[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hfpef\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hfpef":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,81,106,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613741","accelerated-pacing-and-cardiac-filling-pressures-during-exercise-in-patients-with-heart-failure-with-preserved-ejection-fraction-100613741",false,"NCT07270536","Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction","The Impact of Accelerated Pacing and AV-delay Regulation on the Pulmonary Capillary Wedge Pressure During Exercise in Patients With HFpEF","APAVE","Participants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. Heart failure with preserved ejection fraction, defined as one of the below criteria:\n\n   1. EF \\>= 45% and HFA-PEFF score \\>= 5 (Heart Failure Association-Pre-test assessment, Echocardiography and natriuretic peptide, Functional testing, Final etiology; heart failure association of the European Society of Cardiology and the Heart Failure Association (34))\n   2. EF \\>= 45% and H2FPEF score \\>= 6 (Heavy, Hypertensive, Atrial fibrillation, Pulmonary hypertension, Elder, Filling pressure; Mayo Clinic group (35)))\n   3. EF \\>= 45% and\n\n   i. History of heart failure hospitalization after pacemaker implantation or ii.On loop-diuretics at time of inclusion\n4. Having a DDD-pacemaker with LBB area pacing, implanted at least 12 weeks before iCPET\n5. \\>=6 weeks on optimal HFpEF therapy (MRA and SGLT2i) at time of iCPET, unless contraindicated or not tolerated\n6. Sinus rhythm at time of screening and iCPET\n\nParticipants eligible for this Study must not meet any of the following criteria:\n\n1. Participant has a history of:\n\n   1. Evidence of significant pulmonary comorbidity based on abnormal pulmonary function tests (FEV1 \\\u003C60%) or aberrant lung parenchyma more than mild on radiological imaging\n   2. Severe\u002Fsymptomatic valvular diseases\n   3. Severe pulmonary hypertension (PASP \\> 55mmHg estimated by Doppler Echo)\n   4. Unstable arrhythmias (VT, VF)\n   5. Recurrent syncopes after pacemaker implantation\n   6. Permanent atrial fibrillation\n   7. Amyloid cardiomyopathy\n2. Physical inability to perform exercise\n3. More than 1 hospitalization for heart failure in the last year\n4. Resting heart rate\\> 100bpm\n5. At time of iCPET or inclusion: decompensated heart failure, unstable coronary syndrome\n6. Contraindication to central venous access\n\n   1. Severe coagulopathy (e.g., spontaneous INR \\> 2, thrombocytopenia \\\u003C 50,000\u002FµL)\n   2. Local infection or skin infection at the insertion site\n   3. Thrombosis or anatomical abnormalities of the right jugular vein\n   4. Pneumothorax or contralateral lung pathology\n   5. Inability to properly position the patient\n7. Contraindication to arterial access\n\n   1. Thrombosis or occlusion of the target artery\n   2. Raynaud's phenomenon or other vasospastic disorders\n   3. Active infection at the intended insertion site\n   4. Severe coagulopathy (e.g., spontaneous INR \\> 2, thrombocytopenia \\\u003C 50,000\u002FµL)\n   5. Insufficient collateral circulation (e.g., inadequate perfusion in an Allen test)\n8. Contraindications to CPET\n\n   1. ECG signifying myocardial injury\n   2. ECG signifying current or potentially lethal arrhythmias\n   3. Systemic hypotension (e.g. systolic blood pressure \\\u003C 90 mmHg)\n   4. Extreme hypertension (e.g. systolic blood pressure \\> 220 mmHg)\n   5. Syncope, presyncope, or lightheadedness\n   6. SaO2 \\\u003C 88%\n   7. Severely elevated PCWP (\\> 40 mmHg) during exercise","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","What is HFpEF? In heart failure with preserved ejection fraction (HFpEF), the heart pumps well but struggles to relax and fill with blood between beats. This raises the pressure inside the heart, especially during physical activity, causing symptoms like shortness of breath and fatigue - even with light activities like walking or climbing stairs.\n\nWhat is this study about? Recent research suggests that a higher heart rate may help lower this elevated pressure. Many HFpEF patients already have a pacemaker. This study investigates whether simply increasing the pacemaker rate during light exercise can reduce the pressure in the heart.\n\nHow does the study work? We wille measure heart pressures in 20 patients in rest and while cycling using a heart catheter and monitor their breathing. Throughout these measurements, we will gradually increase the pacemaker rate step by step.\n\nWhy does this matter? If a higher pacemaker rate successfully lowers heart pressure, this could offer a simple, drug-free way to improve daily functioning and comfort for thousands of patients with HFpEF, justifying further long-term studies to evaluate effects beyond the immediate changes in heart pressures.",[27],"HFpEF",[29,30,31,32],"Heart Failure with Preserved Ejection Fraction","Accelerated pacing","Chronotropic response","Hemodynamics","RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":37},"2025-12-10",{"date":41,"type":21},"2027-03-01",{"name":43,"class":44},"Universitaire Ziekenhuizen KU Leuven","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100566461","phase-2-triple-combination-therapy-arni-sglt2i-mra-in-advanced-hfpef-100566461","NCT06655480","Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF","Effect on Clinical Status, Structural and Functional Cardiac Parameters and Myocardial Fibrosis of Triple Combination Therapy With a Sodium-glucose Cotransporter 2 Inhibitor, Angiotensin Receptor\u002FNeprilysin Inhibitor and Mineralocorticoid Receptor Antagonist in Patients With Advanced HFpEF","Inclusion Criteria:\n\n1. Signed and data informed consent;\n2. Symptoms and signs of HF;\n3. LV ejection fraction \\> 50%;\n4. NT-proBNP \\> 300 pg\u002FmL (for patients with atrial fibrillation NT-proBNP \\> 900 pg\u002FmL)\n5. LV diastolic dysfunction II-III grade OR\n\nLV diastolic dysfunction I grade and at least 2 out of 4:\n\n* Е\u002Fе' \\> 14\n* LAVi \\> 34 ml\u002Fm2 (for those with persistent atrial fibrillation \\> 40 ml\u002Fm2)\n* PASP \\> 35 mm Hg or TR velocity \\> 2.8 m\u002Fsec\n* LV mass index \\> 95 g\u002Fm2 for women \u002F \\> 115 g\u002Fm2 for men or LV interventricular septum or posterior wall thickness ≥ 1.1 sm OR\n\nChronic atrial fibrillation and at least 3 out of 4:\n\n* Е\u002Fе' \\> 11\n* E-wave velocity \\> 100 sm\u002Fs\n* TR velocity \\> 2.8 sm\u002Fs\n* DT ≤ 160 ms\n\nExclusion Criteria:\n\n1. Evidence of myocardial ischemia during stress echocardiography;\n2. Significant lesions of main coronary arteries;\n3. Atrial fibrillation with resting HR \\> 110 beats\u002Fmin;\n4. Continuous (\\>90 days) treatment with ARNI, SGLTi and\u002For AMR within 12 months prior to screening. The last administration of these drugs must be at least 30 days prior to randomization. Treatment with these drugs should not be interrupted for the purpose of inclusion in the study.\n5. Coronary bypass surgery, stroke or TIA within the last 3 months of screening;\n6. Myocardial infarction or myocardial revascularization within the last 3 months of screening;\n7. Systolic blood pressure \\\u003C 90 mmHg or ≥ 180 mmHg at screening or randomization;\n8. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);\n9. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;\n10. Dyspnea due to non-cardiac causes such as pulmonary disease, anemia, severe obesity, primary valvular, or myocardial diseases;\n11. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);\n12. Primary pulmonary artery hypertension;\n13. Significant left sided structural valve disease;\n14. Anemia (Hb \\\u003C 100 g\u002FL);\n15. Obesity (body mass index \\> 50 kg\u002Fm2);\n16. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2 (CKD-EPI);\n17. Impaired liver function (serum levels of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 × upper limit of normal);\n18. Addison's disease;\n19. Known hypersensitivity to medications used the in the study;\n20. Non-cardiac conditions that complicate\u002Fexclude participation in the study;\n21. Diseases associated with isolated LV insufficiency (idiopathic pulmonary hypertension, chronic thromboembolic pulmonary hypertension, etc.);\n22. Serum\u002Fplasma potassium \\>5.0 mmol\u002FL at screening or randomization or a history of hyperkalemia or acute renal failure during AMR treatment for \\>7 consecutive days leading to discontinuation of AMR treatment.\n23. For patients with diabetes mellitus:\n\n    * Type 1 diabetes mellitus;\n    * Presence of more than 4 episodes of moderate hypoglycemia within the past month or at least one episode of severe hypoglycemia within the past year;\n    * Glycated hemoglobin level \\> 9% or \\\u003C6%","40 Years","80 Years",{"count":56,"type":21},50,[58],"PHASE2","Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with \\[angiotensin receptor\u002Fneprilysin inhibitor \\[ARNI\\] + sodium-glucose cotransporter 2 inhibitor \\[SGLTi\\] + mineralocorticoid receptor antagonist \\[MRA\\]) or with individualized medical therapy \\[SGLTi + renin-angiotensin system inhibitor \\[RASi\\] \\[angiotensin receptor blocker \\[ARB\\] or angiotensin-converting enzyme inhibitor \\[ACE-I\\]), and will be treated for 52 weeks",[27,61,62],"LVDD","Myocardial Fibrosis",[27,64,65,66,67,68,69],"HF","left ventricular hypertrophy","diastolic dysfunction","cardiac reserves","LV filling pressures","myocardial fibrosis","2026-04-21",{"date":72,"type":37},"2026-04-24",{"date":74,"type":37},"2025-03-18",{"date":76,"type":21},"2027-12-31",{"name":78,"class":79},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":80},"100448164","muscle-blood-flow-regulation-in-hfpef-100448164","NCT05115890","Muscle Blood Flow Regulation in HFpEF","Mechanisms of Impaired Skeletal Muscle Blood Flow and Exercise Intolerance in Veterans With Heart Failure With Preserved Ejection Fraction: Efficacy of Knee Extensor Training","Inclusion Criteria:\n\n* Age 18 years or older and able to give written informed consent\n* New York Heart Association (NYHA) functional class II or III\n* Left Ventricular Ejection Fraction (LVEF) \\> 50%\n* Plasma Brain Natriuretic Peptide (BNP) \\>200 pg\u002FmL or NT-proBNP 400 pg\u002FmL at enrollment\n\nExclusion Criteria:\n\n* Prior EF of \\\u003C50%.\n* NYHA Class IV or HF that cannot be stabilized on optimized pharmacotherapy\n* Acute coronary syndrome, infiltrative cardiomyopathy, or myocarditis\n* Patients with HFpEF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction)\n* Orthopedic limitations that would prohibit knee-extensor exercise\n* Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT\n* Women who are pregnant or may become pregnant, but the typical age of female patients with HFpEF will be postmenopausal\n* Current smokers",true,{"count":90,"type":21},35,[24],"Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System. Exercise intolerance is a common complication experienced by patients with HFpEF, perpetuating physical inactivity and accelerating disease progression. This research proposal aims to elucidate mechanisms responsible for inadequate skeletal muscle blood flow and exercise intolerance in patients with HFpEF compared with healthy controls as well as following 8 weeks of exercise training in patients with HFpEF only.",[27],[27,95,96],"Muscle Blood Flow","Exercise Tolerance","2026-04-20",{"date":70,"type":37},{"date":100,"type":37},"2022-07-01",{"date":102,"type":21},"2028-02-29",{"name":104,"class":105},"VA Office of Research and Development","FED",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":80},"100580955","predictors-of-poor-prognosis-in-hfpef-100580955","NCT06844032","Predictors of Poor Prognosis in HFpEF","Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n1. Signed and data informed consent;\n2. New York Heart Association (NYHA) class II-III heart failure;\n3. Left ventricular ejection fraction \\> 50%;\n4. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.\n\nExclusion Criteria:\n\n1. Evidence of myocardial ischemia during stress echocardiography;\n2. Significant lesions of the main coronary arteries;\n3. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);\n4. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;\n5. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);\n6. Primary pulmonary artery hypertension;\n7. Significant left-sided structural valve disease;\n8. Anemia (Hb \\\u003C 100 g\u002FL);\n9. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2 (CKD-EPI);\n10. Non-cardiac conditions that complicate\u002Fexclude participation in the study;\n11. Exacerbation of heart failure less than 3 months prior to study entry.",{"count":114,"type":21},500,"OBSERVATIONAL","Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.",[27],[27,64,66,119,65,67,69],"left ventricle (LV) filling pressures","2026-04-14",{"date":122,"type":37},"2026-04-17",{"date":124,"type":37},"2022-01-31",{"date":126,"type":21},"2026-12-31",{"name":78,"class":79},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100604253","phase-4-clinical-trial-to-evaluate-the-efficacy-and-safety-in-concomitant-administration-of-macitentan-and-dapagliflozin-in-patients-with-heart-failure-with-mildly-reduced-and-preserved-ejection-fraction-hfmref-and-hfpef-and-combined-pre--and-post-capillary-pulmonary-hypertension-cpcph-100604253","NCT07147114","Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)","A Multicenter, Randomized, Double-Blind, Exploratory Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)","Inclusion Criteria:\n\n\\\u003CScreening Visit (Visit 1)\\>\n\n1. A male or female adults aged 19 years or older in South Korea\n2. LVEF greater than 40% on echocardiogram performed within 12 weeks prior to screening\n3. Presence of heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) accompanied by combined pre- and post-capillary pulmonary hypertension (CpcPH)\n4. Meeting all of the following criteria on RHC performed within 48 weeks prior to screening:\n\n   1. mPAP \\> 20 mmHg\n   2. PVR \\> 2 Wood units (WU)\n   3. PAWP \\> 15 mmHg\n5. World Health Organization Functional Class (WHO-FC) II or III at the time of screening\n6. If taking any of the following medications at the time of screening, the participant must have been on a stable dose for at least 3 months:\n\n   1. Renin-angiotensin system inhibitors\n   2. Beta-blockers\n   3. Mineralocorticoid receptor antagonists (aldosterone antagonists)\n   4. Sodium-glucose cotransporter-2 (SGLT2) inhibitors\n   5. Ivabradine\n\n\\\u003CBaseline Visit (Visit 2)\\>\n\n1\\. World Health Organization Functional Class (WHO-FC) II or III at the time of baseline visit\n\nExclusion Criteria:\n\n\\\u003CScreening Visit (Visit 1)\\>\n\n1. Known hypersensitivity to the active ingredients (Macitentan, Dapagliflozin) or any excipients of the investigational medicinal product\n2. Pregnant or breastfeeding women, or those who do not agree to use at least two appropriate contraceptive methods\\* (self or partner) during the clinical trial period and for 30 days after the last administration of the investigational medicinal product (for male participants, those who do not agree to refrain from sperm donation)\n\n   \\*: a. Surgical sterilization (e.g., vasectomy) or intrauterine device (IUD; copper IUD or hormone-releasing intrauterine system), b. Non-oral hormonal contraceptive or spermicide in combination with a barrier method, c. Cervical cap or diaphragm used in combination with a male condom.\n3. Participants with type 1 diabetes mellitus or secondary diabetes mellitus\n4. Participants with metabolic acidosis, such as diabetic ketoacidosis\n5. Participants diagnosed with pulmonary hypertension other than WHO Group 2 pulmonary hypertension (i.e., WHO Group 1, 3, 4, or 5)\n\n   1. Group 1: Pulmonary arterial hypertension\n   2. Group 3: Pulmonary hypertension associated with lung diseases and\u002For hypoxia\n   3. Group 4: Chronic thrombo-embolic pulmonary hypertension\n   4. Group 5: Pulmonary hypertension with unclear and\u002For multifactorial mechanisms\n6. Participants who meet the following criteria on RHC performed within 12 weeks prior to screening:\n\n   a. PAWP ≤ 15 mmHg\n7. History of taking any of the following medications within 4 weeks prior to screening:\n\n   1. Calcium channel blockers\n   2. Endothelin receptor antagonists\n   3. Phosphodiesterase type 5 inhibitors (PDE5i)\n   4. Riociguat\n   5. Prostacyclin (PC) analogs or prostacyclin receptor agonists\n   6. Activin signaling inhibitors\n8. History of any of the following medical conditions, surgeries, or procedures:\n\n   1. Myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention (PCI) within 3 months prior to screening\n   2. Uncontrolled tachycardia (\\>110 bpm) due to atrial fibrillation or atrial flutter\n   3. History of heart transplantation or implantation of a ventricular assist device, or planned to undergo such procedures\n9. eGFR ≤ 30 mL\u002Fmin\u002F1.73 m² or AST or ALT ≥ 2.5 × ULN\n10. Urinary tract infection, genital infection (including fungal infections), or voiding disorder within 24 weeks prior to screening\n11. Hemoglobin \\\u003C 9 g\u002FdL at the time of screening\n12. Participants with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n13. Known hypersensitivity to soybean oil or history of soybean oil allergy\n14. Known hypersensitivity to soy or peanuts\n15. Participation in another clinical trial involving administration\u002Fapplication of an investigational medicinal product or medical device within 3 months prior to screening\n\n\\\u003CBaseline Visit (Visit 2)\\>\n\n1. Participants who, upon re-confirmation of inclusion\u002Fexclusion criteria at the baseline visit, have any disqualifying condition\n2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in this clinical trial","19 Years",{"count":137,"type":21},64,[139],"PHASE4","This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).\n\nThe study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks.\n\nParticipants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.",[142,143,144,27,145],"Combined Pre- and Post-capillary Pulmonary Hypertension","CpcPH","HFmrEF","Group 2 Pulmonary Hypertension","2026-03-30",{"date":148,"type":37},"2026-04-03",{"date":150,"type":37},"2025-11-24",{"date":152,"type":21},"2027-09-30",{"name":154,"class":44},"Gachon University Gil Medical Center",15]